Abstract
e13536 Background: Recent evidence suggests that zoledronic acid (ZOL) inhibits cancer cell proliferation and exerts synergistic antitumor activity at clinically achievable concentrations and have shown the potential to become attractive agents for cancer therapy. This study is the first to report the effects of ZOL on NPC cell lines. Methods: Cell proliferations were determined by MTT assay on four NPC cell lines CNE-1, CNE-2, SUNE-1 and 5–8F. NPC cell lines were seeded in a flat-bottomed 96well plate at 10+4 in 200μl of medium per well and incubated with various concentrations of ZOL for 72 hours. IC50 values for each cell lines were obtained using the non-linear regression program CalcuSyn. IC10 values for ZOL and Cisplatin were calculated from the IC50 curve of each four cell lines. For displaying the synergistic activity concentration equivalent to IC10 of ZOL alone, Cisplatin alone and in combination were added. The entire specimen was incubated for a total of 72 hours and the absorbance was measured at a wavelength of 540nm in a multiwell spectrophotometer. Results: IC5O values (μM) of ZOL on NPC cell lines SUNE-1, CNE-1, CNE-2, 5–8F were 4.56±0.09, 11.96±0.50, 16.73±0.28, 11.01±0.64 respectively. Conclusions: The experiment establishes synergistic effects of ZOL and cisplatin in anti proliferation of NPC cell lines. Thus, ZOL in combination with other cytotoxic agents may be promising therapeutic strategies for NPC with bone metastasis. The efficacy and safety of ZOL for NPC should be verified in early phase clinical trials [Table: see text] No significant financial relationships to disclose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call